Experimental opioid drug more resistant to abuse, company says

07/25/2013 | Medscape (free registration)

Collegium Pharmaceutical said clinical trial data indicate crushed and snorted multiparticulate capsules of its new, extended-release Oxycodone DETERx do not produce a plasma profile sought by drug abusers. An earlier study of the tamper-resistant experimental drug found similar results with crushing and oral use, the company reported.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations